Smad4 and TGFβ1 dependent gene expression signatures in conditional intestinal adenoma, organoids and colorectal

Mirvat Surakhy1, Julia Matheson1, David J Barnes1,2

  • 1Oxford Molecular Pathology Institute, Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford, OX1 3RE, UK.

Scientific Reports
|May 10, 2025
PubMed

Insights

Loss of Mothers against decapentaplegic homolog 4 (Smad4) in mice altered TGF-β1 response in intestinal adenomas. Smad4 loss created distinct gene expression signatures linked to poorer patient survival in colorectal cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Transforming growth factor-beta (TGF-β) signaling plays a dual role in cancer, suppressing growth but promoting invasion and metastasis under specific mutational contexts.
  • Loss of Mothers against decapentaplegic homolog 4 (Smad4) is a key factor influencing TGF-β's paradoxical effects in cancer progression.

Purpose of the Study:

  • To characterize the phenotypic and gene expression differences in murine intestinal adenomas with and without Smad4.
  • To investigate the impact of Smad4 loss on TGF-β1 response in adenoma organoids.
  • To identify potential biomarkers for SMAD4-mutated colorectal cancer.

Main Methods:

  • Conditional knockout of Apc and Smad4 in murine intestinal epithelium using Lgr5-CreERT2.
  • Generation and characterization of ApcΔ/ΔSmad4Δ/Δ and ApcΔ/ΔSmad4+/+ adenoma organoids.
  • TGF-β1 dose-response assays on organoids.
  • Bulk and single-cell RNA sequencing (scRNAseq) of adenoma tissues.
  • Analysis of The Cancer Genome Atlas (TCGA) cohorts for human colorectal cancer data.

Main Results:

  • ApcΔ/ΔSmad4Δ/Δ mice exhibited reduced small intestinal adenoma burden but developed large, non-metastatic caecal adenomas.
  • Smad4-deficient adenoma organoids showed significantly increased resistance to TGF-β1-induced growth arrest and cell death compared to Smad4-wildtype organoids.
  • TGF-β1 treatment in Smad4-deficient adenomas led to decreased Id1 and increased Spp1 expression.
  • scRNAseq identified an expansion of Lgr5low, Pak3high, and Id1low progenitor populations in Smad4-deficient adenomas.
  • Only 7 of 76 Smad4 and TGF-β1-dependent genes in murine models were differentially expressed in human SMAD4-mutated colorectal cancer, including ID1.
  • Lower SMAD4, ID1 expression, and higher SPP1 and PAK3 expression correlated with poorer patient survival.

Conclusions:

  • Loss of Smad4 alters TGF-β1 signaling in intestinal adenomas, leading to distinct cellular phenotypes and gene expression profiles.
  • Specific gene expression signatures, including ID1low, SPP1high, and PAK3high, associated with Smad4 deficiency in mice, are also linked to poor prognosis in human colorectal cancer.
  • These findings highlight the potential of Smad4-dependent gene expression signatures as functional biomarkers for classifying SMAD4-mutated colorectal cancer subtypes.